Krebs K M, Geyer M A
Department of Psychology, University of California at San Diego, La Jolla 92093-0804.
Psychopharmacology (Berl). 1994 Jan;113(3-4):429-37. doi: 10.1007/BF02245219.
Like hallucinogenic 5-HT2 agonists, LSD (d-lysergic acid diethylamide) produces characteristic decreases in locomotor activity and investigatory behaviors of rats tested in a novel environment. Because LSD is an agonist at both 5-HT1A and 5-HT2 receptors, however, the respective influences of these different receptors in the behavioral effects of LSD remain unclear. In particular, the paucity of selective 5-HT1A antagonists has made it difficult to assess the specific contribution of 5-HT1A receptors to the effects of LSD. An alternative approach to the delineation of receptor-specific effects is the use of cross-tolerance regimens. In the present studies, rats were pretreated with saline, 8-hydroxy-2(di-n-propylamino)-tetralin (8-OH-DPAT) (0.5 mg/kg SC), 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) (1.0 mg/kg SC), or LSD (60 micrograms/kg SC), every 12 h for 5 or 8 days. Thirty-six hours later, rats were tested in a behavioral pattern monitor 10 min after injection of saline, 0.5 mg/kg 8-OH-DPAT, 1.0 mg/kg DOI, or 60 micrograms/kg LSD. As expected, tolerance to the decreases in locomotor activity produced by acute administrations of 8-OH-DPAT, DOI, or LSD occurred when rats were pretreated chronically with 8-OH-DPAT, DOI, or LSD, respectively. Furthermore, pretreatment with either 8-OH-DPAT or DOI produced cross-tolerance to LSD. These results support the hypothesis that the effects of LSD in this model reflect a combination of 5-HT1A and 5-HT2 effects and support the view that there is an interaction between 5-HT1A and 5-HT2 receptors.
与致幻性5-羟色胺2(5-HT2)激动剂一样,麦角酸二乙酰胺(LSD)会使在新环境中测试的大鼠的运动活动和探究行为出现特征性降低。然而,由于LSD是5-羟色胺1A(5-HT1A)和5-HT2受体的激动剂,这些不同受体在LSD行为效应中的各自影响仍不清楚。特别是,选择性5-HT1A拮抗剂的匮乏使得难以评估5-HT1A受体对LSD效应的具体贡献。描绘受体特异性效应的另一种方法是使用交叉耐受方案。在本研究中,大鼠每12小时接受一次生理盐水、8-羟基-2(二正丙基氨基)四氢萘(8-OH-DPAT)(0.5毫克/千克,皮下注射)、1-(2,5-二甲氧基-4-碘苯基)-2-氨基丙烷(DOI)(1.0毫克/千克,皮下注射)或LSD(60微克/千克,皮下注射)预处理,持续5天或8天。36小时后,在注射生理盐水、0.5毫克/千克 8-OH-DPAT、1.0毫克/千克 DOI或60微克/千克 LSD 10分钟后,在行为模式监测仪中对大鼠进行测试。正如预期的那样,当大鼠分别长期用8-OH-DPAT、DOI或LSD预处理时,对急性给予8-OH-DPAT、DOI或LSD所产生的运动活动降低产生了耐受性。此外,用8-OH-DPAT或DOI预处理对LSD产生了交叉耐受性。这些结果支持了这样的假设,即LSD在该模型中的效应反映了5-HT1A和5-HT2效应的组合,并支持了5-HT1A和5-HT2受体之间存在相互作用的观点。